Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2013 1
2014 2
2015 3
2016 1
2017 2
2018 2
2019 4
2020 4
2021 3
2022 4
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Management of scleroderma renal crisis.
Nagaraja V. Nagaraja V. Curr Opin Rheumatol. 2019 May;31(3):223-230. doi: 10.1097/BOR.0000000000000604. Curr Opin Rheumatol. 2019. PMID: 30870219 Review.
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.
Roofeh D, Brown KK, Kazerooni EA, Tashkin D, Assassi S, Martinez F, Wells AU, Raghu G, Denton CP, Chung L, Hoffmann-Vold AM, Distler O, Johannson KA, Allanore Y, Matteson EL, Kawano-Dourado L, Pauling JD, Seibold JR, Volkmann ER, Walsh SLF, Oddis CV, White ES, Barratt SL, Bernstein EJ, Domsic RT, Dellaripa PF, Conway R, Rosas I, Bhatt N, Hsu V, Ingegnoli F, Kahaleh B, Garcha P, Gupta N, Khanna S, Korsten P, Lin C, Mathai SC, Strand V, Doyle TJ, Steen V, Zoz DF, Ovalles-Bonilla J, Rodriguez-Pinto I, Shenoy PD, Lewandoski A, Belloli E, Lescoat A, Nagaraja V, Ye W, Huang S, Maher T, Khanna D. Roofeh D, et al. Among authors: nagaraja v. Rheumatology (Oxford). 2023 May 2;62(5):1877-1886. doi: 10.1093/rheumatology/keac557. Rheumatology (Oxford). 2023. PMID: 36173318 Free PMC article.
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Spiera R, et al. Arthritis Rheumatol. 2023 Sep;75(9):1608-1618. doi: 10.1002/art.42510. Epub 2023 Jun 15. Arthritis Rheumatol. 2023. PMID: 37098795 Free article. Clinical Trial.
A 64-Year-Old Man with Joint Pain.
McBride N, Swaminathan S, Nagaraja V. McBride N, et al. Among authors: nagaraja v. NEJM Evid. 2023 Jun;2(6):EVIDmr2200337. doi: 10.1056/EVIDmr2200337. Epub 2023 May 23. NEJM Evid. 2023. PMID: 38320131
Measuring response in the gastrointestinal tract in systemic sclerosis.
Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Khanna D, et al. Among authors: nagaraja v. Curr Opin Rheumatol. 2013 Nov;25(6):700-6. doi: 10.1097/01.bor.0000434668.32150.e5. Curr Opin Rheumatol. 2013. PMID: 24047604 Free PMC article. Review.
34 results